The Pharma Data

MAY 15, 2023

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Drug Discovery World

NOVEMBER 8, 2023

Among these, the molecule ISM042-2-048 showed potential as a new liver cancer drug due to its effective binding with CDK20. AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. Psychology Today 25 January 2023. Ren F, Ding X, Zheng M, et al.

Clinical Trials 182

Clinical Trials Trials Disease Medical Schools 182

Drug Discovery World

JULY 11, 2023

Tim Lowery , President, JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology. So, where do we go from here to realise their potential in life sciences?

Science 100

Science Drugs FDA Engineering 100

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. This is because many proteins do not have small-molecule binding sites. This is not the first deal for RNA therapeutics for Genentech.

RNA 52

RNA Small Molecule DNA Licensing 52

Drug Target Review

NOVEMBER 6, 2023

These regimens frequently include one or two small molecule inhibitors and immuno-oncology (IO) therapies, such as monoclonal antibodies and T-cell engagers. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. References Blood Cancer UK.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

LifeSciVC

DECEMBER 6, 2022

These hair clip-like molecules clamp onto DNA, thereby turning many genes on and off. As Darnell observed, the prospect of being able to regulate Transcription Factor function holds the potential to reframe the way we treat disease but achieving that goal with traditional small molecule screening approaches is impossible.

Small Molecule 40

Small Molecule DNA Regulations Science 40

Drug Discovery World

JUNE 5, 2023

DDW’s Megan Thomas comments on the event. New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk.

Small Molecule 130

Small Molecule Treatment Science Disease 130

Drug Target Review

JUNE 19, 2024

The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. Just like small molecules and antibodies, cell therapies are changing how we treat patients.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Discovery World

JANUARY 3, 2023

Matthew Clark , CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Artificial intelligence. Conclusion.

DNA 130

DNA Targeted Protein Degradation Small Molecule Pharma Companies 130

PLOS: DNA Science

JUNE 22, 2023

“If you’re an adult with newly diagnosed non-small cell lung cancer that’s spread and tests positive for PDL1 without an abnormal EGFR your first option could be …” announces a TV ad for a pair of targeted cancer drugs, flying by so fast that I doubt many patients can grasp anything.

Drugs 52

Drugs Small Molecule DNA Bioethics 52

LifeSciVC

AUGUST 5, 2024

The genomic capabilities that were brought online for drug discovery (cheaper & faster next-gen DNA sequencing) did not diminish the need for biologists and translational scientists in target and patient selection, respectively. One final parallel to 2001.

Molecular Biology 90

Molecular Biology Production Small Molecule Drug Development 90

Drug Discovery World

SEPTEMBER 9, 2024

The transformative power of AI While Foundation Models (FMs), including Large Language Models (LLMs) and image-based models, may not exhibit true intelligence, their potential to revolutionise fields like drug discovery and materials science is undeniable. Small Language Models (SLMs) are gaining traction, particularly in the life sciences.

Drugs 162

Drugs Bioinformatics Computational Chemistry International 162

DrugBaron

JULY 19, 2022

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

Small Molecule 100

Small Molecule Drugs DNA Pharma Companies 100

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. Noria) and PSMA Therapeutics Inc.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

LifeSciVC

MARCH 1, 2023

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more recent times has been romanticized in movies like Field of Dreams , but the concept also holds true in many areas of science.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

Drug Discovery World

NOVEMBER 17, 2022

It is believed that the term synthetic biology was created in 1970 by geneticist, Waclaw Szybalski 1 as work was being carried out on the development of DNA sequencing and synthesis techniques. A study published in Science 3 outlines how the compound, named cilagicin, works well in mice and employs a novel mechanism to attack MRSA, C.

Engineering 130

Engineering Molecular Biology Synthetic Chemistry DNA 130

Drug Discovery World

APRIL 15, 2023

The American Association for Cancer Research (AACR) Annual Meeting is taking place at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023.

Virus 130

Virus Clinical Trials Trials Therapies 130

Drug Target Review

JULY 18, 2023

I think it is astonishing that The Human Genome Project was completed exactly 20 years ago and DNA was discovered by Franklin and published by Watson and Crick exactly 70 years ago, yet that 10 percent success rate has still not improved. Pharmaceutical companies are an absolutely pivotal part of the life sciences industry and ecosystem.

Drug Development 98

Drug Development Drugs Pharmaceutical Companies Clinical Development 98

The Pharma Data

APRIL 11, 2023

Both small molecule inhibitors in Immuno-Oncology are being jointly developed in a strategic research alliance with the German Cancer Research Center (DKFZ) in Heidelberg, Germany. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Research 40

Research Clinical Trials Small Molecule Pharmacokinetics 40

The Pharma Data

MARCH 18, 2022

By manipulating the microbes’ DNA, they programmed gene circuits that control the bacteria surface, building a molecular “cloak” that encapsulates the bacteria. They control the iCAP system by giving it an external cue – a small molecule called IPTG – that allows for programmable and dynamic alteration of the E.

Engineering 52

Engineering Small Molecule Drugs Therapies 52

KIF1A

AUGUST 20, 2024

Susannah is being treated with an Antisense Oligonucleotide (ASO) : To break down the term, this is a molecule designed with a sequence of 20 (oligo, “few”) letters of DNA (nucleotide) that match a sequence on the mutant KIF1A RNA (Antisense) and knock it down. With gratitude, in the Year of Pioneers.

Science 52

Science Treatment Therapies Small Molecule 52

Drug Discovery World

AUGUST 9, 2024

Self-assembled monolayers in high-density biochip arrays Zachary Gurard-Levin, PhD, Science Director, Discovery, Charles River says that: “Historically, MS instruments have not always been amenable to the components required for optimal activity in a biochemical or binding reaction. The company also makes Orbitrap-based LC-MS instruments.

Biophysical Assays 147

Biophysical Assays Small Molecule Drugs DNA 147

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Rapid and accurate DNA synthesis .

DNA 246

DNA Engineering Drugs Vaccine 246

Sygnature Discovery

JUNE 17, 2024

Our skilled protein science team can provide in-house production of proteins to support all these assay formats if needed. Microscale Thermophoresis (MST) Microscale Thermophoresis (MST) is a technology that uses fluorescently labelled proteins to analyse small molecule binding in solution.

Small Molecule 52

Small Molecule Fragment Screening DNA Science 52

Codon

JUNE 11, 2024

And unlike traditional DNA sequencers, which parse genetic material by breaking it up into fragments and interpreting it chunk-by-chunk, a nanopore device unspools a long strand of DNA and reads it all at once. A scientist can isolate DNA and load up a flow cell in fifteen minutes. Nanopore devices work incredibly fast.

DNA 77

DNA Engineering RNA Small Molecule 77

Drug Discovery World

JULY 8, 2024

For decades, the life sciences community held the belief that RNA was merely the intermediary messenger (mRNA) between DNA and protein, a dogma that has been the foundation of biology. RNA aptamers have the potential to overcome this challenge through the use of a reversal agent to quickly and effectively stabilise patients.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147

Drug Discovery World

SEPTEMBER 6, 2022

It’s no surprise that investors have wanted to gain a portion of what is an exciting and emerging field on science, one which offers many opportunities to treat a wide range of diseases. The Skills Demand Survey Report presents a lack of graduate life sciences apprenticeship programmes as a key barrier. But challenges remain.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

APRIL 30, 2024

It’s worth noting that the approach of small molecules interacting with mRNA biology represents a relatively new and potentially broader and more effective strategy. For example, mRNA testing can offer deeper insights compared to DNA and give researchers a better understanding of gene expression in relation to certain cancers.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

APRIL 29, 2024

Dr Andrew Lewis, Chief Scientific Officer; Kieron Hall, Chief Marketing Officer; and Eric Bironneau, Chief Business Officer, Quotient Sciences: Lewis has held various scientific leadership positions at Quotient and was previously Director of Novel Drug Delivery Technologies at Ipsen.

Drugs 130

Drugs Small Molecule Bioinformatics Pharmaceuticals 130

Drug Discovery World

JUNE 6, 2023

He looks after all of Sygnature’s integrated and standalone oncology projects, making sure that the company is doing the best science for its customers, driving programmes forward as efficiently as possible towards the clinic. But frankly, up until this point, all the clinical data has been quite disappointing.

Small Molecule 130

Small Molecule DNA RNA Research 130

Codon

APRIL 2, 2023

Basic Science *No evidence for a common blood microbiome based on a population study of 9,770 healthy humans. But now, by studying DNA extracted from microbes in the blood of almost 10,000 healthy people, this paper shows that there is no such thing. Read Transcription factors bind to DNA and control gene expression.

DNA 52

DNA RNA Engineering Licensing 52

Drug Target Review

JULY 31, 2023

I was ‘pre-med’ and got really interested in the science and especially the integration of chemistry and art. I struggled with going to graduate school in art conservation science, ie, the science of art, or more general chemistry, and I decided to do chemistry because it had broader opportunities.

DNA 98

DNA Small Molecule Science Cell Biology 98

Drug Target Review

AUGUST 2, 2024

This observation prompted us to search for small molecules that might de-repress TERT, restore physiological levels, and potentially impact hallmarks of ageing. How did the researchers identify the small molecule compound that could restore TERT levels?

Small Molecule 59

Small Molecule Regulations Clinical Trials Disease 59

Dark Matter Blog

AUGUST 31, 2020

The majority of small molecule drugs induce their therapeutic effects by seeking out and binding to their intended target while avoiding most other molecules in the dense milieu of the cell interior. Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA.

RNA 52

RNA Small Molecule Bioinformatics Computational Chemistry 52

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. He holds a PhD in Biomedical Sciences from Queen’s University of Belfast (Northern Ireland). Fu Y, Ho M.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126